Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 459

1.

Structural Implications of STAT3 and STAT5 SH2 Domain Mutations.

de Araujo ED, Orlova A, Neubauer HA, Bajusz D, Seo HS, Dhe-Paganon S, Keserű GM, Moriggl R, Gunning PT.

Cancers (Basel). 2019 Nov 8;11(11). pii: E1757. doi: 10.3390/cancers11111757. Review.

2.

Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts.

Garousi J, Huizing FJ, Vorobyeva A, Mitran B, Andersson KG, Leitao CD, Frejd FY, Löfblom J, Bussink J, Orlova A, Heskamp S, Tolmachev V.

Sci Rep. 2019 Oct 17;9(1):14907. doi: 10.1038/s41598-019-51445-w.

3.

The stromal microenvironment provides an escape route from FLT3 inhibitors through the GAS6-AXL-STAT5 axis.

Orlova A, Neubauer HA, Moriggl R.

Haematologica. 2019 Oct;104(10):1907-1909. doi: 10.3324/haematol.2019.225862. No abstract available.

4.

Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer.

Mitran B, Varasteh Z, Abouzayed A, Rinne SS, Puuvuori E, De Rosa M, Larhed M, Tolmachev V, Orlova A, Rosenström U.

Cancers (Basel). 2019 Sep 14;11(9). pii: E1371. doi: 10.3390/cancers11091371.

5.

Circular Dichroism Spectroscopy as a Powerful Tool for Unraveling Assembly of Chiral Nonluminescent Aggregates of Photosensitizer Molecules on Nanoparticle Surfaces.

Visheratina AK, Purcell-Milton F, Gun'ko YK, Orlova A.

J Phys Chem A. 2019 Sep 19;123(37):8028-8035. doi: 10.1021/acs.jpca.9b05500. Epub 2019 Sep 10.

PMID:
31469561
6.

Ceramic Mineral Waste-Forms for Nuclear Waste Immobilization.

Orlova AI, Ojovan MI.

Materials (Basel). 2019 Aug 19;12(16). pii: E2638. doi: 10.3390/ma12162638. Review.

7.

Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody-DM1 Drug Conjugates.

Ding H, Altai M, Rinne SS, Vorobyeva A, Tolmachev V, Gräslund T, Orlova A.

Cancers (Basel). 2019 Aug 14;11(8). pii: E1168. doi: 10.3390/cancers11081168.

8.

[The study of fenspiride: goals and objectives for chemical and toxicological studies].

Kalekin RA, Orlova AM, Savchuk SA, Barsegyan SS.

Sud Med Ekspert. 2019;62(4):37-41. doi: 10.17116/sudmed20196204137. Russian.

PMID:
31407704
9.

Evaluation of Tumor-Targeting Properties of an Antagonistic Bombesin Analogue RM26 Conjugated with a Non-Residualizing Radioiodine Label Comparison with a Radiometal-Labelled Counterpart.

Oroujeni M, Abouzayed A, Lundmark F, Mitran B, Orlova A, Tolmachev V, Rosenström U.

Pharmaceutics. 2019 Aug 2;11(8). pii: E380. doi: 10.3390/pharmaceutics11080380.

10.

Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer.

Abouzayed A, Yim CB, Mitran B, Rinne SS, Tolmachev V, Larhed M, Rosenström U, Orlova A.

Pharmaceutics. 2019 Jul 23;11(7). pii: E358. doi: 10.3390/pharmaceutics11070358.

11.

Ambidextrous helical nanotubes from self-assembly of designed helical hairpin motifs.

Hughes SA, Wang F, Wang S, Kreutzberger MAB, Osinski T, Orlova A, Wall JS, Zuo X, Egelman EH, Conticello VP.

Proc Natl Acad Sci U S A. 2019 Jul 16;116(29):14456-14464. doi: 10.1073/pnas.1903910116. Epub 2019 Jul 1.

PMID:
31262809
12.

Optimal composition and position of histidine-containing tags improves biodistribution of 99mTc-labeled DARPin G3.

Vorobyeva A, Schulga A, Konovalova E, Güler R, Löfblom J, Sandström M, Garousi J, Chernov V, Bragina O, Orlova A, Tolmachev V, Deyev SM.

Sci Rep. 2019 Jun 28;9(1):9405. doi: 10.1038/s41598-019-45795-8.

13.

Indirect Radioiodination of DARPin G3 Using N-succinimidyl-Para-Iodobenzoate Improves the Contrast of HER2 Molecular Imaging.

Vorobyeva A, Schulga A, Rinne SS, Günther T, Orlova A, Deyev S, Tolmachev V.

Int J Mol Sci. 2019 Jun 21;20(12). pii: E3047. doi: 10.3390/ijms20123047.

14.

Potent and specific fusion toxins consisting of a HER2‑binding, ABD‑derived affinity protein, fused to truncated versions of Pseudomonas exotoxin A.

Liu H, Lindbo S, Ding H, Altai M, Garousi J, Orlova A, Tolmachev V, Hober S, Gräslund T.

Int J Oncol. 2019 Jul;55(1):309-319. doi: 10.3892/ijo.2019.4814. Epub 2019 May 28.

PMID:
31180549
15.

Structural and functional consequences of the STAT5BN642H driver mutation.

de Araujo ED, Erdogan F, Neubauer HA, Meneksedag-Erol D, Manaswiyoungkul P, Eram MS, Seo HS, Qadree AK, Israelian J, Orlova A, Suske T, Pham HTT, Boersma A, Tangermann S, Kenner L, Rülicke T, Dong A, Ravichandran M, Brown PJ, Audette GF, Rauscher S, Dhe-Paganon S, Moriggl R, Gunning PT.

Nat Commun. 2019 Jun 7;10(1):2517. doi: 10.1038/s41467-019-10422-7.

16.

[Medical rehabilitation of patients with alcohol dependency at risk of parental rights deprivation].

Agibalova TV, Akhmetzyanov II, Khaeva RF, Udachina GL, Nedobylskiy OV, Orlova AV, Gurevich GL.

Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(3):65-69. doi: 10.17116/jnevro201911903165. Russian.

PMID:
31089098
17.

Selection of the optimal macrocyclic chelators for labeling with 111In and 68Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6.

von Witting E, Garousi J, Lindbo S, Vorobyeva A, Altai M, Oroujeni M, Mitran B, Orlova A, Hober S, Tolmachev V.

Eur J Pharm Biopharm. 2019 Jul;140:109-120. doi: 10.1016/j.ejpb.2019.05.008. Epub 2019 May 10.

18.

Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist 177 Lu-DOTAGA-PEG2 -RM26.

Mitran B, Rinne SS, Konijnenberg MW, Maina T, Nock BA, Altai M, Vorobyeva A, Larhed M, Tolmachev V, de Jong M, Rosenström U, Orlova A.

Int J Cancer. 2019 Dec 15;145(12):3347-3358. doi: 10.1002/ijc.32401. Epub 2019 May 23.

PMID:
31077356
19.

Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake.

Rosestedt M, Andersson KG, Rinne SS, Leitao CD, Mitran B, Vorobyeva A, Ståhl S, Löfblom J, Tolmachev V, Orlova A.

Sci Rep. 2019 May 1;9(1):6779. doi: 10.1038/s41598-019-43145-2.

20.

Comparison of tumor‑targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2.

Vorobyeva A, Sсhulga A, Konovalova E, Güler R, Mitran B, Garousi J, Rinne S, Löfblom J, Orlova A, Deyev S, Tolmachev V.

Int J Oncol. 2019 Apr;54(4):1209-1220. doi: 10.3892/ijo.2019.4712. Epub 2019 Feb 11.

21.

Site-specific conjugation of recognition tags to trastuzumab for peptide nucleic acid-mediated radionuclide HER2 pretargeting.

Westerlund K, Vorobyeva A, Mitran B, Orlova A, Tolmachev V, Karlström AE, Altai M.

Biomaterials. 2019 May;203:73-85. doi: 10.1016/j.biomaterials.2019.02.012. Epub 2019 Feb 14.

22.

Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of 68Ga-Labeled Tracers.

Dahlsson Leitao C, Rinne SS, Mitran B, Vorobyeva A, Andersson KG, Tolmachev V, Ståhl S, Löfblom J, Orlova A.

Int J Mol Sci. 2019 Mar 2;20(5). pii: E1080. doi: 10.3390/ijms20051080.

23.

Cell Metabolism Control Through O-GlcNAcylation of STAT5: A Full or Empty Fuel Tank Makes a Big Difference for Cancer Cell Growth and Survival.

Rauth M, Freund P, Orlova A, Grünert S, Tasic N, Han X, Ruan HB, Neubauer HA, Moriggl R.

Int J Mol Sci. 2019 Feb 27;20(5). pii: E1028. doi: 10.3390/ijms20051028. Review.

24.

[Public healthcare responsibilities of ophthalmologists according to professional regulations].

Tregubov VN, Fettser EI, Siplivy VI, Orlova AA.

Vestn Oftalmol. 2018;134(6):124-128. doi: 10.17116/oftalma2018134061124. Russian.

PMID:
30721210
25.

Hydrogen peroxide in the reactions of cancer cells to cisplatin.

Nerush AS, Shсhukina KM, Balalaeva IV, Orlova AG.

Biochim Biophys Acta Gen Subj. 2019 Apr;1863(4):692-702. doi: 10.1016/j.bbagen.2019.01.013. Epub 2019 Jan 25.

PMID:
30690121
26.

Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111.

Rinne SS, Leitao CD, Mitran B, Bass TZ, Andersson KG, Tolmachev V, Ståhl S, Löfblom J, Orlova A.

Sci Rep. 2019 Jan 24;9(1):655. doi: 10.1038/s41598-018-36827-w.

27.

The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease.

Kosack L, Wingelhofer B, Popa A, Orlova A, Agerer B, Vilagos B, Majek P, Parapatics K, Lercher A, Ringler A, Klughammer J, Smyth M, Khamina K, Baazim H, de Araujo ED, Rosa DA, Park J, Tin G, Ahmar S, Gunning PT, Bock C, Siddle HV, Woods GM, Kubicek S, Murchison EP, Bennett KL, Moriggl R, Bergthaler A.

Cancer Cell. 2019 Jan 14;35(1):125-139.e9. doi: 10.1016/j.ccell.2018.11.018.

28.

Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties.

Deyev S, Vorobyeva A, Schulga A, Proshkina G, Güler R, Löfblom J, Mitran B, Garousi J, Altai M, Buijs J, Chernov V, Orlova A, Tolmachev V.

Mol Pharm. 2019 Mar 4;16(3):995-1008. doi: 10.1021/acs.molpharmaceut.8b00922. Epub 2019 Feb 8.

PMID:
30608701
29.

[Training of dentists in public healthcare in accordance with professional standards].

Tregubov VN, Kuznetsova MY, Orlova AA.

Stomatologiia (Mosk). 2018;97(6):10-12. doi: 10.17116/stomat20189706110. Russian.

PMID:
30589417
30.

Raster-scan optoacoustic angiography of blood vessel development in colon cancer models.

Orlova A, Sirotkina M, Smolina E, Elagin V, Kovalchuk A, Turchin I, Subochev P.

Photoacoustics. 2018 Nov 23;13:25-32. doi: 10.1016/j.pacs.2018.11.005. eCollection 2019 Mar.

31.
32.

Pharmacologic IL-6Rα inhibition in cholangiocarcinoma promotes cancer cell growth and survival.

Kleinegger F, Hofer E, Wodlej C, Golob-Schwarzl N, Birkl-Toeglhofer AM, Stallinger A, Petzold J, Orlova A, Krassnig S, Reihs R, Niedrist T, Mangge H, Park YN, Thalhammer M, Aigelsreiter A, Lax S, Garbers C, Fickert P, Rose-John S, Moriggl R, Rinner B, Haybaeck J.

Biochim Biophys Acta Mol Basis Dis. 2019 Feb 1;1865(2):308-321. doi: 10.1016/j.bbadis.2018.11.006. Epub 2018 Nov 9.

33.

[The efficacy of botulinum therapy in treatment of delayed facial palsy after resection of vestibular schwannoma].

Akulov MA, Tanyashin SV, Shimansky VN, Usachev DY, Orlova OR, Zakharov VO, Karnaukhov VV, Kolycheva MV, Khat'kova SE, Latysheva KD, Orlova AS.

Zh Vopr Neirokhir Im N N Burdenko. 2018;82(5):81-87. doi: 10.17116/neiro20188205181. Russian.

PMID:
30412160
34.

Detection of a Disorder-Induced Bose-Einstein Condensate in a Quantum Spin Material at High Magnetic Fields.

Orlova A, Mayaffre H, Krämer S, Dupont M, Capponi S, Laflorencie N, Paduan-Filho A, Horvatić M.

Phys Rev Lett. 2018 Oct 26;121(17):177202. doi: 10.1103/PhysRevLett.121.177202.

35.

Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours.

Garousi J, Lindbo S, Borin J, von Witting E, Vorobyeva A, Oroujeni M, Mitran B, Orlova A, Buijs J, Tolmachev V, Hober S.

Eur J Pharm Biopharm. 2019 Jan;134:37-48. doi: 10.1016/j.ejpb.2018.11.004. Epub 2018 Nov 5.

36.

Using a personalized clinical decision support system for bromdihydrochlorphenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers.

Zastrozhin MS, Sorokin AS, Agibalova TV, Grishina EA, Antonenko AР, Rozochkin IN, Duzhev DV, Skryabin VY, Galaktionova TE, Barna IV, Orlova AV, Aguzarov AD, Savchenko LM, Bryun EA, Sychev DA.

Hum Psychopharmacol. 2018 Nov;33(6):e2677. doi: 10.1002/hup.2677. Epub 2018 Oct 25.

PMID:
30357930
37.

The use of the novel glycosyl acceptor and supramer analysis in the synthesis of sialyl-α(2-3)-galactose building block.

Nagornaya MO, Orlova AV, Stepanova EV, Zinin AI, Laptinskaya TV, Kononov LO.

Carbohydr Res. 2018 Dec;470:27-35. doi: 10.1016/j.carres.2018.10.001. Epub 2018 Oct 9.

PMID:
30343245
38.

Affibody‑mediated imaging of EGFR expression in prostate cancer using radiocobalt‑labeled DOTA‑ZEGFR:2377.

Mitran B, Andersson KG, Lindström E, Garousi J, Rosestedt M, Tolmachev V, Ståhl S, Orlova A, Löfblom J.

Oncol Rep. 2019 Jan;41(1):534-542. doi: 10.3892/or.2018.6792. Epub 2018 Oct 15.

PMID:
30320363
39.

Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs.

Altai M, Leitao CD, Rinne SS, Vorobyeva A, Atterby C, Ståhl S, Tolmachev V, Löfblom J, Orlova A.

Cells. 2018 Oct 11;7(10). pii: E164. doi: 10.3390/cells7100164.

40.

Preclinical Evaluation of [68Ga]Ga-DFO-ZEGFR:2377: A Promising Affibody-Based Probe for Noninvasive PET Imaging of EGFR Expression in Tumors.

Oroujeni M, Garousi J, Andersson KG, Löfblom J, Mitran B, Orlova A, Tolmachev V.

Cells. 2018 Sep 18;7(9). pii: E141. doi: 10.3390/cells7090141.

41.

Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model.

Mitran B, Güler R, Roche FP, Lindström E, Selvaraju RK, Fleetwood F, Rinne SS, Claesson-Welsh L, Tolmachev V, Ståhl S, Orlova A, Löfblom J.

Theranostics. 2018 Aug 7;8(16):4462-4476. doi: 10.7150/thno.24395. eCollection 2018.

42.

Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors.

Altai M, Liu H, Ding H, Mitran B, Edqvist PH, Tolmachev V, Orlova A, Gräslund T.

J Control Release. 2018 Oct 28;288:84-95. doi: 10.1016/j.jconrel.2018.08.040. Epub 2018 Aug 30.

PMID:
30172673
43.

[Expression of genes for neurotransmitter transporters in astrocytes in different brain regions in experiment].

Shusharina NN, Patrushev MV, Silina EV, Stupin VA, Litvitsky PF, Orlova AS.

Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(6):58-64. doi: 10.17116/jnevro20181186158. Russian.

PMID:
30040802
44.

The role of SAGA coactivator complex in snRNA transcription.

Popova VV, Orlova AV, Kurshakova MM, Nikolenko JV, Nabirochkina EN, Georgieva SG, Kopytova DV.

Cell Cycle. 2018;17(15):1859-1870. doi: 10.1080/15384101.2018.1489175. Epub 2018 Aug 15.

45.

Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab.

Orlova A, Bass TZ, Rinne SS, Leitao CD, Rosestedt M, Atterby C, Gudmundsdotter L, Frejd FY, Löfblom J, Tolmachev V, Ståhl S.

Mol Pharm. 2018 Aug 6;15(8):3394-3403. doi: 10.1021/acs.molpharmaceut.8b00393. Epub 2018 Jul 25.

PMID:
29995421
46.

Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors.

Vorobyeva A, Bragina O, Altai M, Mitran B, Orlova A, Shulga A, Proshkina G, Chernov V, Tolmachev V, Deyev S.

Contrast Media Mol Imaging. 2018 Jun 6;2018:6930425. doi: 10.1155/2018/6930425. eCollection 2018.

47.

Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy.

Vorobyeva A, Westerlund K, Mitran B, Altai M, Rinne S, Sörensen J, Orlova A, Tolmachev V, Karlström AE.

Sci Rep. 2018 Jun 25;8(1):9643. doi: 10.1038/s41598-018-27886-0.

48.

Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with 111In and 68Ga.

Lindbo S, Garousi J, Mitran B, Vorobyeva A, Oroujeni M, Orlova A, Hober S, Tolmachev V.

Mol Pharm. 2018 Jul 2;15(7):2674-2683. doi: 10.1021/acs.molpharmaceut.8b00204. Epub 2018 Jun 20.

PMID:
29865791
49.

Wideband linear detector arrays for optoacoustic imaging based on polyvinylidene difluoride films.

Subochev P, Prudnikov M, Vorobyev V, Postnikova A, Sergeev E, Perekatova V, Orlova A, Kotomina V, Turchin I.

J Biomed Opt. 2018 May;23(9):1-5. doi: 10.1117/1.JBO.23.9.091408.

50.

Multimodal approach in assessment of the response of breast cancer to neoadjuvant chemotherapy.

Pavlov MV, Kalganova TI, Lyubimtseva YS, Plekhanov VI, Golubyatnikov GY, Ilyinskaya OY, Orlova AG, Subochev PV, Safonov DV, Shakhova NM, Maslennikova AV.

J Biomed Opt. 2018 May;23(9):1-11. doi: 10.1117/1.JBO.23.9.091410.

Supplemental Content

Loading ...
Support Center